p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer

British Journal of Cancer

Volumn 81, Issue 4, 1999, Pages 733-740

  Ferrandina, G ^a   Fagotti, A ^a   Salerno, M G ^a   Natali, P G ^b   Mottolese, M ^b   Maneschi, F ^c   De Pasqua, A ^a   Benedetti Panici, P ^c   Mancuso, S ^a   Scambia, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Cytoreduction; Ovarian cancer; p53; Response to chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

ADULT; AGED; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032886486     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690756     Document Type: Article

References (35)

1. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM and Gazdar AF (1992) Expression of mutant p53 proteins in lung cancer correlates with the loss of p53 gene mutation. Oncogene 7: 743-749
2. Bouvet M. Ellis LM, Nishizaki M, Fijiwara T, Tiu W, Bucana CD, Fang B, Lee JJ and Roth J (1998) Adenovirus-mediated wild-type p53 gene transfer down regulates vascular endothelial growth factor expresion and inhibits angiogenesis in human colon cancer. Cancer Res 58: 2288-2292
3. Bristow RE, Langasse LD, Karlan BY (1996) Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Cancer 78: 2049-2062
4. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Kaye SB and Vojtesek B (1993) Increased accumulation of p53 protein in cisplatin resistant ovarian cell lines. Int J Cancer 55: 678-684
5. Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gaggetti O, Genazzani AR and Bevilacqua G (1997) p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 75: 230-235
6. Cox DR (1970) Analysis of Binary Data, Methuen: London
7. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M and Lohrs U (1996) Bel-2 expression, p53 accumulation and apoptosis in ovarian carcinomas. Am J Clin Pathol 105: 341-349
8. Dong Y, Walsh MD, McGuckin MA, Cummings MC, Gabrielli BG, Wright GR, Hurst T, Khoo SK and Parsons PG (1997) Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer 74: 407-414
9. Eccles DM, Brett L, Lessels A, Gruber L, Lane D, Steel CM and Leonard RC (1992) Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 65: 40-44
10. Geisler JP, Geisler HE, Wiemann MC, Givens SS, Zhou Z and Miller GS (1997) Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 66: 435-438
11. Gjerset RA, Turla ST, Sobol RE, Scalise JT, Mercola D, Collins M and Hopkins PJ (1993) Use of wild type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 14: 275-285
12. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann J and Roche PC (1994) Prognostic significance of p53 immunostaining in epithelial ovarian cancer, J Clin Oncol 12: 64-69
13. Heintz APM (1996) Surgery in ovarian cancer: the concept of cytoreductive surgery Curr Opin Obst Gynecol 8: 8-11
14. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B and Oberg K (1994) p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow-cytometry. Gynecol Oncol 53: 301-306
15. Herod JJO, Eliopoulos AG, Warwick J, Niedobitek G, Kern DJ and Young LS (1996) The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178-2184
16. Katsaros D, Levesque M, Genta F, Durando A, Arisio R, Yu H, Diamandis EP and Massobrio M (1998) Prognostic and predictive value of p53 and waf-1 expression in epithelial ovarian cancer Proc Am Ass Cancer Res 39 (abstract 1355)
17. Klemi PJ, Pylkkanen L, Kiilholma P, Kurvinen K and Joensuu H (1995) p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76: 1201-1208
18. Kohler MF, Kerns BM, Humphrey PA, Marks JR, Bast RC and Berchuck A (1993) Mutation and overexpression of p53 in early stage epithelial ovarian cancer. Obstet Gynecol 81: 643-650
19. Kupryjanczyk J, Bell DA, Yandell DW, Scully RE, Thor AD (1994) p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 102: 671-676
20. Kupryjanczyk J, Thor A, Beauchamp R, Merritt V, Edgerton SM, Bell DA and Yandell DW (1993) p53 gene mutations and protein accumulation in human ovarian cancer, Proc Natl Acad Sci USA 90: 4961-4965
21. Levesque MA, Katsarods D, Yu H, Zola P, Sismondi P, Giardina G and Diamandis EP (1995) Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75: 1327-1338
22. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising its consideration. Cancer Chemother Rep 50: 163-170
23. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Penec JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC and Berchuck A (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51: 2979-2984
24. Marx D, Meden H, Ziemek T, Lenthe T, Kuhn W and Schauer A (1998) Expression of the p53 tumour suppressor gene as prognostic marker in platinum treated patients with ovarian cancer. Eur J Cancer 34: 845-850
25. Michieli P, Chedid M, Lin D, Pierce JM, Mercer WE and Givol D (1994) Induction of waf1/cip1 by a p53-independent pathway. Cancer Res 54: 3391-3395
26. Momand J, Zambetti GP, Olson DC, Gorge D and Levine HJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245
27. Perego P, Giarola M, Righetti SC, Supino R, Cesarini C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562
28. Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM and Shingleton HM (1991) Primary surgical therapy of ovarian cancer: how much and when. Gynecol Oncol 40: 195-200
29. Reles A, Schmider A, Press MF, Schonborn I, Friedmann W, Huber-Schumacher S, Stronmeyer T and Lintenegger W (1996) Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol 122: 489-494
30. Righetti, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Oriana S, Comarotti M, Bohm S, Bresciani GC, Spatti G and Zunino F (1996) Comparative study of p53 gene mutations, protein accumulation, and response cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689-693
31. Rohlke P, Milde-Langosch K, Weyland C, Pichlmeier U, Janet W and Loning T (1997) p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity. J Cancer Res Clin Oncol 123: 496-501
32. Scambia G, Benedetti-Paniei P, Ferrandina G, Distefano M, Salerno G, Romanini ME, Fagotti A and Mancuso S (1995) Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 72: 361-366
33. van der Zee AGJ, Hollema H, Suurmeijer AJH, Kraus M, Sluiter WJ, Willanse PH, Alders JG and de-Vries EF (1995) Value of p-glycoprotein, glutathione S-transferase pi, c-crbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13: 70-78
34. waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry. Int J Gynecol Pathol 16: 149-155
35. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. WHO: Geneva, pp. 16-21